‘Personal preference’: Market reacts to GLP-1 pills


As the first oral preparations hit pharmacy shelves, experts comment on how patients will decide and key differences between the two soon-to-be-stocked tablets The emergence of two Glucagon-like peptide-1 receptor agonist (GLP-1) tablets on the Australian market is expected to offer choice and reduce patient cost over time, but in the short-term, experts believe patients’

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Forgot Password?Why do I need to login & stay in?

Previous ‘Is this the pricing we are competing with?’
Next The week in review